ArticleThe oncologist2025
Influence of tamoxifen on ocular morphology and function.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overview of ocular toxicities associated with breast cancer therapies.Breast cancer research and treatment · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTamoxifen, a commonly used selective estrogen receptor antagonist for adjuvant therapy in hormone receptor-positive breast cancer, can cause ocular side effects due to estrogen receptors in ocular structures. This prospective study explores its impact on ocular morphology and function. MATERIALS AND
methodsThis prospective, non-interventional, cross-sectional study explores the effects of tamoxifen on ocular morphology, visual acuity, and quality. Examinations included objective refractometry, visual acuity, contrast sensitivity, color vision, visual field tests, corneal topography, optical coherence tomography, autofluorescence, and slit lamp biomicroscopy. Participants completed a health questionnaire. Statistical analysis, using linear or logistic (mixed) regression, compared tamoxifen's effects to a control group.
resultsA total of 102 patients were included: 90 in the study group and 12 controls. The duration of tamoxifen therapy showed a clinically relevant impact on the visual field, with a mean loss variance change of 0.045 dB² per week (95% CI [0.012 dB²; 0.079 dB²]). Corneal thickness decreased by -0.12 μm per week (95% CI [-0.20 μm; -0.031 μm]) with longer therapy duration. Fourteen patients received additional aromatase inhibitors, and this group showed clinically significant reductions in both visual acuity and contrast vision. No correlation was observed between tamoxifen intake and visual acuity, contrast vision, color vision, mean defect in visual fields, retinal thickness, macular morphology, or slit-lamp biomicroscopy findings.
conclusionAccording to this study, tamoxifen intake influences corneal thickness and perimetry, which are two parameters associated with glaucoma development. Regular ophthalmological glaucoma controls could be useful in tamoxifen patients, especially if glaucoma is already known.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.